US Patent

US12491164 — Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof

Formulation · Assigned to Impax Laboratories LLC · Expires 2034-10-07 · 8y remaining

Vulnerability score 38/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a muco-adhesive, controlled release oral solid formulation of levodopa and/or esters of levodopa with carbidopa.

USPTO Abstract

The invention provides an oral solid formulation comprising (a) a plurality of controlled release components comprising (i) a core comprising a mixture of levodopa and at least one pharmaceutically acceptable excipient, (ii) a controlled release coating surrounding the core, (iii) a muco-adhesive coating surrounding the controlled release coating and (iv) an enteric coating surrounding the muco-adhesive coating; and (b) one or more immediate release components comprising levodopa. The oral solid formulation also contains carbidopa and about 80% to 100% of the carbidopa in the oral solid formulation is present in the one or more immediate release components.

Drugs covered by this patent

Patent Metadata

Patent number
US12491164
Jurisdiction
US
Classification
Formulation
Expires
2034-10-07
Drug substance claim
No
Drug product claim
Yes
Assignee
Impax Laboratories LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.